Lead Product(s) : Avoplacel
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pluristem Announces End of Patient Enrollment in its Phase I Hematology Study
Details : The Phase I multi-center, open-label, 3 cohort dose-escalating study is evaluating the safety of intramuscular (IM) injections of PLX-R18 cells in 20 subjects, with incomplete hematopoietic recovery persisting for at least 3 months after HCT.
Product Name : PLX-R18
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 19, 2020
Lead Product(s) : Avoplacel
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable